By David Rubin, Commercial and Business Development Director, Cytiva
The cost of doing business in biopharma has continuously increased over time, especially as new challenges in drug development and manufacturing emerge with the pursuit of new and complex modalities. To remain competitive, biomanufacturing companies must discover ways to drive innovation while also improving efficiency. One way to do this is through the effective utilization of data across the product life cycle, as this approach offers greater visibility into the workflow, driving better decision making and facilitating issue management and resolution.
However, while stakeholders across the industry recognize intuitively that improving the digital maturity of a plant is beneficial, many have difficulty quantifying the benefits and struggle to justify the incremental investment. To help address these challenges, Cytiva has partnered with the independent software company, Biopharm Services (BPS), to model the costs and associated benefits of increasing digital maturity for monoclonal antibody processes in a biopharma plant utilizing single-use technology, ultimately evaluating the total cost of ownership required to achieve a higher level of digital plant maturity.
Download the full article to better understand what factors are taken into consideration during this evaluation and what Cytiva and BPS discovered about the benefits and costs of increasing digital maturity to an interim level of 2.5 compared to other levels in Biophorum’s Digital Plant Maturity Model. The result for your facility could be a higher level of digital maturity at a lower cost and commitment than expected.